Why has Goldman Sachs downgraded GE HealthCare? By Investing.com

Goldman Sachs downgraded GE HealthCare to Neutral from Buy and cut its 12-month price target to $65 from $81, citing higher raw material costs, supply chain pressure, tariffs, and weaker China demand. The firm now expects only 3%–4% organic revenue growth in 2026 and about 5% EPS growth near term, with stronger double-digit EPS growth delayed until 2027. Recent strength in diagnostics and imaging is being offset by underperformance in patient care solutions and a softer macro backdrop.

Analysis

This is less about one analyst call and more about a margin reset story for premium medtech names exposed to global industrial input inflation. The important second-order effect is that GEHC’s earnings sensitivity to supply-chain and tariff noise makes its multiple vulnerable even if revenue holds up; in this tape, investors are paying less for “good execution” when the market believes exogenous costs can erase operating leverage for multiple quarters. That tends to spill over into adjacent names with similar manufacturing footprints, especially those with heavier China exposure or more complex BOMs.

The downgrade also signals a broader bifurcation inside healthcare equipment: imaging and diagnostics can still earn a premium, but patient-care and lower-differentiation franchises are becoming the weakest link as hospitals resist price increases. If management cannot offset costs with mix improvement, the market will likely re-rate GEHC as a low-growth industrial rather than a healthcare compounder. That creates a valuation gap versus software-like medtech peers with more recurring revenue and less tariff sensitivity.

The near-term risk is not demand collapse but estimate drift over the next 2-3 quarters: each incremental cost pass-through delay compresses 2026 EPS, and that is enough to keep the stock range-bound even if quarterly headlines remain “okay.” A reversal would require either a durable easing in freight/raw-material inflation or clearer evidence that China weakness has bottomed, neither of which is likely to be priced before the next couple of prints. The consensus may be underappreciating how long it takes for cost inflation to wash through a capital equipment P&L, which means the earnings downdraft can persist longer than the top-line narrative suggests.

Key Decisions for Investors

• Short GEHC on rallies into the next 1-2 weeks; use a 3-6 month horizon for the cost inflation/estimate-reset trade. Risk/reward favors the short if the stock still trades at a premium to slower-growth industrials despite falling EPS expectations.
• Pair trade: long HOLX or ISRG vs short GEHC over the next quarter. The cleaner balance sheets and less China/tariff sensitivity should outperform if medtech multiples compress on macro margin pressure.
• Buy 3-6 month put spreads on GEHC rather than outright puts to express continued multiple compression with defined theta bleed. Best entry is after any relief rally tied to broader healthcare strength.
• Avoid chasing GS on this headline; it reads as neutral for the platform. If anything, use the call as confirmation that sell-side revision risk is now skewed negative across globally manufactured healthcare equipment names.